Sotabase

Career

· Professor, University of Liverpool2011–
· Senior Lecturer, University of Liverpool2009–2011
· Lecturer, University of Liverpool2004–2009
· Honorary Lecturer, University of Liverpool2003–2004
· Post-doctoral Researcher, University of Liverpool2002–2004
· Doctor of Philosophy (PhD), Pharmacology, University of Liverpool1998–2002
· Master of Science (MSc), Pharmacology, University of Liverpool1997–1998
· Bachelor of Science (BSc), Molecular and Cellular Biology, University of Bath1993–1997

Publications (392)

Predictors of kidney tubular dysfunction in HIV-infected patients treated with tenofovir: a pharmacogenetic study.
Clinical Infectious Diseases · 2009
254
cited
Enabling Genomic Revolution in Africa
The Genetics of African Populations in Health and Disease · 2019
244
cited
Nrf2 is overexpressed in pancreatic cancer: implications for cell proliferation and therapy
Molecular Cancer · 2011
237
cited
FXR inhibition may protect from SARS-CoV-2 infection by reducing ACE2
Nature · 2022
233
cited
Impact of CYP2B6 983T>C polymorphism on non-nucleoside reverse transcriptase inhibitor plasma concentrations in HIV-infected patients.
Journal of Antimicrobial Chemotherapy · 2008
185
cited
HIV protease inhibitors are substrates for OATP1A2, OATP1B1 and OATP1B3 and lopinavir plasma concentrations are influenced by SLCO1B1 polymorphisms
Pharmacogenetics & Genomics · 2010
178
cited
On the issue of transparency and reproducibility in nanomedicine
Nature Nanotechnology · 2019
177
cited
Plasma HIV-1 RNA detection below 50 copies/ml and risk of virologic rebound in patients receiving highly active antiretroviral therapy.
Clinical Infectious Diseases · 2012
162
cited
The SLCO1B1 rs4149032 Polymorphism Is Highly Prevalent in South Africans and Is Associated with Reduced Rifampin Concentrations: Dosing Implications
Antimicrobial Agents and Chemotherapy · 2011
148
cited
Carbamazepine is not a substrate for P-glycoprotein.
British Journal of Clinical Pharmacology · 2001
146
cited
Strengths, weaknesses, opportunities and challenges for long acting injectable therapies: Insights for applications in HIV therapy.
Advanced Drug Delivery Reviews · 2016
140
cited
Prioritization of Anti‐SARS‐Cov‐2 Drug Repurposing Opportunities Based on Plasma and Target Site Concentrations Derived from their Established Human Pharmacokinetics
Clinical pharmacology and therapy · 2020
133
cited
A potent SARS-CoV-2 neutralising nanobody shows therapeutic efficacy in the Syrian golden hamster model of COVID-19
Nature Communications · 2021
129
cited
Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Tuberculosis · 2007
129
cited
Induction of Influx and Efflux Transporters and Cytochrome P450 3A4 in Primary Human Hepatocytes by Rifampin, Rifabutin, and Rifapentine
Antimicrobial Agents and Chemotherapy · 2013
128
cited
Cytochrome P450 2B6 (CYP2B6) and constitutive androstane receptor (CAR) polymorphisms are associated with early discontinuation of efavirenz-containing regimens.
Journal of Antimicrobial Chemotherapy · 2011
119
cited
Comparison of the induction profile for drug disposition proteins by typical nuclear receptor activators in human hepatic and intestinal cells
British Journal of Pharmacology · 2008
116
cited
Genetic variants of ABCC10, a novel tenofovir transporter, are associated with kidney tubular dysfunction.
Journal of Infectious Diseases · 2011
115
cited
Transport of gabapentin by LAT1 (SLC7A5).
Biochemical Pharmacology · 2013
114
cited
A living WHO guideline on drugs to prevent covid-19
British medical journal · 2021
112
cited
Sotabase